Chronic lymphocytic leukemia (CLL) is a type of cancer that affects lymphocytes. It can be challenging to detect CLL early because it does not cause symptoms in its early stages. CLL can follow ...

Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma. A comparison of the second-generation Bruton tyrosine ...

If you’ve received a diagnosis of chronic lymphocytic leukemia (CLL), stress can take a toll on your health. Exercising, finding activities you enjoy, and seeking out support can lower stress ...

Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic ...

Despite higher melanoma risk, MBL patients show similar stage and Breslow thickness at diagnosis compared to non-MBL patients. Patients with low-count chronic lymphocytic leukemia phenotype ...

A medical oncologist, a thoracic surgeon, and a patient advocate discuss what an early-stage non-small lung cancer diagnosis ... and patient Jim Plotkin give comprehensive insights into Chronic ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic ...

U.S. sales of BRUKINSA totaled $504 million in the third quarter of 2024, representing growth of 87% over the prior-year ...

SEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCLCoverage leverages new Medicare episode pricing ...

The global leukemia therapeutics treatment market has seen considerable growth, progressing from USD 14,504.8 million in 2022 to USD 15,246.7 million in 2023. With a projected compound annual growth ...

We do not see sufficient promising late-stage blockbusters in its pipeline to warrant ... Sonrotoclax is a second-generation BCL-2 inhibitor for relapsed/refractory chronic lymphocytic leukemia or ...